Whales with a lot of money to spend have taken a noticeably bullish stance on Madrigal Pharmaceuticals.
Looking at options history for Madrigal Pharmaceuticals MDGL we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 45% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $193,787 and 16, calls, for a total amount of $1,092,167.
Latest Startup Investment Opportunities:
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $460.0 for Madrigal Pharmaceuticals over the last 3 months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Madrigal Pharmaceuticals stands at 290.77, with a total volume reaching 472.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Madrigal Pharmaceuticals, situated within the strike price corridor from $90.0 to $460.0, throughout the last 30 days.
Madrigal Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MDGL | CALL | SWEEP | BULLISH | 03/15/24 | $90.00 | $140.5K | 0 | 41 |
| MDGL | CALL | TRADE | BULLISH | 06/21/24 | $160.00 | $113.0K | 48 | 10 |
| MDGL | CALL | SWEEP | BULLISH | 03/15/24 | $90.00 | $94.5K | 0 | 68 |
| MDGL | CALL | SWEEP | BULLISH | 03/15/24 | $90.00 | $93.7K | 0 | 74 |
| MDGL | CALL | SWEEP | BULLISH | 03/15/24 | $90.00 | $93.6K | 0 | 24 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Current Position of Madrigal Pharmaceuticals
- Currently trading with a volume of 278,509, the MDGL's price is up by 1.95%, now at $259.2.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 68 days.
What Analysts Are Saying About Madrigal Pharmaceuticals
In the last month, 4 experts released ratings on this stock with an average target price of $251.0.
- In a cautious move, an analyst from B. Riley Securities downgraded its rating to Sell, setting a price target of $155.
- Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $347.
- In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $347.
- In a cautious move, an analyst from B. Riley Securities downgraded its rating to Sell, setting a price target of $155.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Madrigal Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
